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Summary The effects of combinations of dipyridamole, an effective blocker of the salvage pathway of DNA
synthesis, and 8 types of anti-cancer drugs on the growth of human T, B and myeloid leukaemia/lymphoma
cell lines in vitro were examined. In combinations, dipyridamole and vincristine (VCR), and dipyridamole and
vindesine had synergistic inhibitory effects. Dipyridamole reduced the efflux of VCR from cells and enhanced
their VCR accumulation in a dose-dependent manner at concentrations of up to 10pM in the lymphoid cell
lines, MOLT-3 and BL-TH, and of up to at least 20pM in the myeloid cell line, ML-1. Dipyridamole also
enhanced the accumulation of VCR in PHA-stimulated and un-stimulated lymphocytes of normal donors, but
efflux of VCR was more rapid from normal lymphocytes than from cultured cell lines. It is proposed that
combination therapy with dipyridamole plus VCR should be effective in the treatment of leukaemia and
lymphoma.
Dipyridamole exerts an antiplatelet and anti-thrombotic
action in vivo (Emmons et al., 1965), and was first used
clinically for the treatment of angina pectoris (Pabst, 1959).
It has pharmacological effects and biological properties
including blockade of nucleoside transport and inhibition of
cyclic AMP phosphodiesterase (Harker & Kadatz, 1983).
There are reports that the salvage pathway of DNA
synthesis is important for proliferation of tumour cells, and
that purine and pyrimidine nucleosides protect tumour cells
from inhibitors of the de novo pathway of DNA synthesis
(Pinedo et al., 1976; Howell et al., 1981). Dipyridamole
inhibits the transports of purine and pyrimidine nucleosides
through membranes of normal and malignant mammalian
cells (Scholtissek, 1968; Berlin & Oliver, 1975), and
suppresses the incorporation of 3H-thymidine (TdR) into
human peripheral blood lymphocytes (Pazdur et al., 1980;
Farmer & Prager, 1981). Therefore, it has been suggested to
block the salvage pathway of DNA synthesis. Dipyridamole
was also shown to be cytotoxic for hepatoma 3924A cells
(Zhen et al., 1983), but, anti-cancer drugs that block the
salvage pathway have not been used clinically. Dipyridamole
also modulates intracellular uptake and toxicity of
cytarabine (King ct al., 1984).
Recently, combinations of several anti-cancer drugs have
been used clinically to obtain increased therapeutic effects
and fewer adverse effects. Dipyridamole is reported to show
increased anti-tumour effects in vitro when given in combi-
nation with various anti-cancer drugs (Fischer et at., 1984;
King & Howell, 1982; Zhen et al., 1983; Cabral et al., 1984).
Therefore, we investigated the effects of combinations of
dipyridamole and various anti-cancer agents on the growth
of human haematologic malignant cell lines.
We also examined the mechanism of the synergistic
inhibitory effects of dipyridamole and vincristine (VCR) on
the growth of these cell lines, and compared the magnitude
of the effects of the combinations on normal blood
lymphocytes and haemopoietic malignant cells in vitro.
Materials and methods
Ctells
Three cultured haemopoietic malignant cell lines of different
lineage were used. These were MOLT-3, derived from a T-
cell acute lymphocytic leukaemia (Minowada ct al., 1972),
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BL-TH derived from a Japanese boy with Burkitt's
lymphoma and established in our laboratory in 1984, and
ML-1, derived from a case of acute myelocytic leukaemia
(Minowada, 1981). BL-TH cells are immature B-cells with
la-like antigen, BI antigen and surface immunoglobulin (y,
(5) and show t(8; 22) chromosomal abnormality. Cells were
cultured at 37'C in a humidified atmosphere of 5% CO2 in
air. These cells were routinely maintained under conditions
of logarithmic growth in RPMI-1640 medium (Nissui,
Tokyo) supplemented with 10% foetal calf serum
(Boehringer, Mannheim), lOOpgml aminobenzyl penicillin
and l0pgml-1 gentamicin. The cell doubling times of these
cell lines were as follows: MOLT-3, 24.6+2.6h; BL-TH,
22.2+2.8h; ML-1, 36.6+3.4h.
Heparinized blood was obtained from four normal adult
donors, and the mononuclear cells were separated by Ficoll-
Paque (Pharmacia, Uppsala) gradient centrifugation.
The mononuclear cells were cultured in medium con-
taining l ugml- I phytohemagglutinin (PHA) for 72 h, and
induction of blastogenesis of the lymphocytes by PHA was
confirmed by demonstration of increased uptake of '4C-
TdR.
Chemicals
Dipyridamole was purchased from Boehringer Ingelheim
Ltd (Bridgefield, CT), and VCR from Shionogi Co.
(Osaka, Japan). 3H-VCR (4.8 Ci mmol- 1) and 14C-TdR
(50mCimmol-1) were from Amersham International
(Arlington Heights, IL). PHA was from Wellcome Co.
(Beckenham, UK).
Growt,th inhibition
Cells in the logarithmic phase of growth were seeded into
triplicate test tubes containing 1 ml of culture medium with
an anti-cancer drug and/or dipyridamole. Culture was
initiated at cell concentrations of 2 x 105 cellsml- I (MOLT-3
and BL-TH), and 2.5 x 105 cellsml - (ML-1). After culture
for 72h, growth in test tubes with and without anti-cancer
drugs was measured.
The combined effect of drugs was classified into 4
categories: protection, sub-additive, additive and supra-
additive, based on an isobologram by the method of Steel
and Peckham (1979). We used the term supra-additive as
synergism.
Uptake of 3H-VCR by cells in the presence of dipyridamole
Samples of 1 x 106 cultured cells of MOLT-3, BL-TH or
ML-1, and PHA-stimulated and unstimulated lymphocytes
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were centrifuged at 5OOg for 5 min, and resuspended in
culture medium with or without dipyridamole. The cells were
preincubated for 30min and then pulsed with 0.05 ,uCi of
3H-VCR (9.5 nM VCR, final concentration). After incubation
for 2h, the cells were washed 3 times with saline, re-
suspended in 0.5 ml of distilled water, and stored at -70°C.
Radioactivity was determined in a liquid scintillation counter
after addition of 5 ml of ACS-IT (Amersham) and the rate of
incorporation was expressed as the cpm per total cells
(cpm 10-6 cells). The amount of intracellular VCR was
calculated from this value and specific radioactivity of 3H-
VCR (4.8Cimmol-1).
Cellular uptake of 14C-TdR
For measurement of 14C-TdR incorporation, samples of
1 x 106 PHA-stimulated and unstimulated mononuclear cells
were pulsed for 2 h with 0.05 4uCi of 14C-TdR, and cpm 10-6
cells were determined as in experiments with 3H-VCR.
Efflux of3H-VCRfrom cells
Samples of 1 x 106 MOLT-3, BL-TH, ML-1, and PHA-
stimulated and unstimulated lymphocytes were cultured for
12 h in medium containing 0.05,Ci 3H-VCR with or without
dipyridamole. After removal of these compounds, the cells
were cultured in medium with or without 10 liM dipyri-
damole, and their intracellular radioactivities were measured
at intervals.
Statistical analysis
Student's t-test was employed to calculate the significance of
differences.
Results
Effects ofdipyridamole plus various anti-cancer drugs
The effects of dipyridamole plus VCR, vindesine, adria-
mycin, L-asparaginase, hydroxyurea, etoposide, methotrexate
and cytarabine were tested. Dipyridamole plus VCR or
vindesine showed synergistic inhibitory effects on the
growths of 3 haematologic cell lines, MOLT-3, BL-TH and
ML-1, while the other combinations showed only additive or
protective effects on the growth of these lines (Table I).
Therefore, we studied the effect of the combination of
dipyridamole and VCR in more detail.
As shown in Figure 1, dipyridamole inhibited the growth
of MOLT-3, BL-TH and ML-1 cells in a dose-dependent
manner. The IC50 values were 27.2 +2.5,M for MOLT-3,
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Figure 1 Effect of dipyridamole on the growth of cell lines,
MOLT-3 (0), BL-TH (A) and ML-1 (C]1). Cell numbers were
counted after 72h culture in medium with dipyridamole. Points
are mean values for triplicate assays; s.d.s were within 10% of
the mean values.
21.1+2.0OM for BL-TH and 14.3+1.9,UM for ML-1 cells.
Dose-dependent inhibition of VCR and VCR plus 10 pM
dipyridamole on the growth of the 3 cell lines are shown in
Figure 2. The patterns of growth inhibition by these two
agents are of the shoulder-type (Steel & Peckham, 1979). We
then analysed the type of inhibition by combinations of
various concentrations of VCR and dipyridamole. As shown
in Figure 3, cell growth (as a percentage of that of control
cells) was as follows: MOLT-3 cells - 48.1 +2.2% in 1.08 nM
VCR plus 6.85,UM dipyridamole, 3.0+0.8% in 0.72nM VCR
plus 13.6,M dipyridamole and 26.3 + 1.1% in 0.36 nM VCR
plus 20.4pM. BL-TH cells- 7.0+0.5% in 1.2nM VCR plus
5.25 pM dipyridamole, 2.9 + 1.1% in 0.8 nM VCR plus
10.5pM dipyridamole and 0% in 0.4nM VCR plus 15.75pM
dipyridamole. ML-l cells - 0% in 1.125nM VCR plus 3.6 M
dipyridamole, 12.0+1 .2% in 0.75nM VCR plus 7.2pM di-
pyridamole and 29.4+2.5% in 0.375nM VCR plus 10.8pM
dipyridamole. These data suggest that in combination, VCR
and dipyridamole have synergistic inhibitory effects on the
growth of human leukaemia and lymphoma cell lines. At
half their IC50 concentrations these 2 drugs in combination
had supra-additive effects. On the other hand, in combi-
nation at one quarter of the IC50 concentration of di-
pyridamole and three quarters that of VCR, they had
Table I Inhibition of growth of cultured cell lines by VCR and dipyridamole
IC50 values
MOLT-3 BL-TH ML-J
Drug Dip(-) Dip(+) Dip (-) Dip(+) Dip ) Dip(+)
VCR (nM) 1.42+0.09 0.94+0.06 1.58 +0.10 0.12+0.01 1.91 +0.08 0.13 +0.01
VDS (nM) 2.3 +0.06 0.55+0.01 2.20+0.3 0.6+0.03 0.90+0.01 0.10+0.01
ADM (nM) 4.3+0.1 4.0+0.04 6.8 +0.7 2.3+0.3 47.5+1.0 29.0+ 3.0
L-asp (KU ml 1) 0.2+0.01 0.12+0.02 0.49+0.1 0.38+0.03 0.6+0.02 0.09+0.001
Hu (nM) 114+2 108+4 47+3 42+1 170+23 162+12
Etoposide (/M) 42+4 27+1 119+4 52+8 180+15 155+20
MTX (nM) 8.0+0.1 13.3+0.1 9.5+0.2 14.5+0.2 5.5+0.1 4.5+0.1
Ara-C (nM) 7.5+0.7 > 100 19.0+2.0 > 100 24.0+0.3 > 100
Ara-C (nM)+ I ,UM Dip 93 + 10 84+2 83+4
IC50, 50% inhibitory concentration; Dip, IO M dipyridamole treatment.
%Inhibitin I increase in cell number with drugs 0olnhibition 1- x 10000.
increase in cell number without drugs/
VCR, vincristine; VDS, vindesine; ADM, adriamycin; L-asp, L-asparaginase; Hu, hydroxyurea; MTX, methotrexate,
and Ara-C, cytarabine.GROWTH INHIBITION BY DIPYRIDAMOLE
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Figure 2 Effects of VCR on growth of MOLT-3 (0), BL-TH
(A) and ML-1 (D-1) cells and of VCR plus 10 M dipyridamole
on growth of MOLT-3 (0), BL-TH (A) and ML-l (A) cells.
Growth (log % control) was determined after culture for 72h.
Points are means for triplicate cultures; s.d.s were within 10.6%
of the mean values.
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Figure 3 Combined effects of various concentrations of VCR
and dipyridamole on cell growth. Cell growth (% control) was
determined after culture for 72h. Points are means for triplicate
cultures; s.d.s were within 10% of the mean values. Symbols:
MOLT-3 (0), BL-TH (A) and ML-l (El).
additive effects on cell growth of MOLT-3 as judged by the
method of Steel and Packham (1979).
Effkct of dipEricldamole on 3H-VCR accunmulation in normal
lyvnlphoc ites ani (cultured cells
The intracellular VCR concentration was correlated with the
extracellular concentration of VCR and the cell number, and
increased linearly with up to 0.2pCi of VCR (38 nM, final
concentration) and 2 x 106 cells ml 'in all 3 cell lines tested.
As shown in Figure 4, the accumulation of VCR in the 3
cell lines was increased in a dose-dependent manner by
dipyridamole at concentrations up to 10pM with MOLT-3
and BL-TH cells, and up to at least 20pM with ML-1 cells.
Figure 5 shows the accumulation of VCR in these cells
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Figure 4 Effects of dipyridamole on 3H-VCR accumulation in
the 3 cultured cell lines. Cultures were preincubated for 30min
and then incubated for 6h in the presence of 0.05,uCi 3H-VCR
(9.5 nm VCR, final concentration) and 10Hm dipyridamole.
Points are means +s.ds for triplicate cultures. Symbols: MOLT-
3 (O), BL-TH (A) and ML-1I (H).
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Figure 5 Effects of dipyridamole on 3H-VCR accumulation in
cells. After preincubation of the cells for 30min, 0.05,pCi 3H-
VCR (9.5nm VCR, final concentration) was added to medium
with or without 10piM dipyridamole. Symbols: MOLT-3 (0),
BL-TH (A) and ML-1 (-) cells cultured with dipyridamole;
MOLT-3 (0), BL-TH (A) and ML-1 (C]) cells cultured without
dipyridamole. Points are means for triplicate determinations;
s.d.s were within 9.6% of the mean values. Significant differences
from the control values (*P<0.01) after 12h were analyzed by
the t-test.
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during incubation with or without 1O pM dipyridamole. The
accumulation of VCR in 12 h was - 1.64 to 1.93 times
higher in cells incubated with dipyridamole than in those
incubated without dipyridamole (P<0.01), and were 2.15 to
2.36 times higher after culture for 24h.
The accumulation of 3H-VCR in PHA-stimulated and
unstimulated lymphocytes from normal donors was also
examined. Table II shows that in 12 h dipyridamole
enhanced VCR accumulation 1.65-fold in PHA-stimulated
lymphocytes (P<0.01) and 1.15-fold in unstimulated
lymphocytes (not significant) compared with that in control
cultures.
Table 11 3H-VCR accumulation in normal lympho-
cytes
pmol 10 6 lymphocytes
Treatment PHA (-) PHA (+)
'4C-TdR 1.18+0.15 54.72+4.56
3H-VCR 0.20+0.06 0.40+0.05
3H-VCR +dip 0.23 +0.06 0.66+0.07
Cells were pulsed with '4C-TdR for 2 h and with
3H-VCR for 12h. Values are means +s.d. for 4
independent determinations.
Effects ofdipyridamole on efflux of 3H- VCR
As shown in Figure 6, after loading with 3H-VCR and then
incubation for 12h in the absence of VCR, the intracellular
radioactivities in MOLT-3, BL-TH and ML-1 cell lines with
10pM dipyridamole were 15%, 20% and 19% higher than
the respective values in these cells cultured without
dipyridamole (P<0.01).
When MOLT-3, BL-TH and ML-1 cells, and PHA-
stimulated and unstimulated lymphocytes had been cultured
for 12h in medium containing VCR and dipyridamole, their
intracellular radioactivities 12h after removal of VCR and
dipyridamole were 52.9+3.5%, 52.2+3.2%, 65.5+4.5%,
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Figure 6 Effects of dipyridamole on 3H-VCR efflux. The 3 cell
lines were cultured in the presence of 0.05pCi 3H-VCR (9.5nM
VCR, final concentration) for 12h. Then, after removal of the
isotope, they were cultured in medium with 10 pM dipyridamole
[MOLT-3 (S), BL-TH (A) and ML-1 (-)] or without dipyrida-
mole [MOLT-3 (0), BL-TH (A) and ML-1 (El)]. Points are
means for triplicate determinations; s.d.s were within 8.0% of the
mean values. The significances of differences from control values
at 12h (*P<0.01) were analyzed by the t-test.
Table III Effect of dipyridamole on efflux of 3H-VCR
pmolJO 6 cells
Cell line Treatment (A) Treatment (B) (%)
MOLT-3 1.90+0.16 1.00+0.16 (52.9+3.5)
BL-TH 1.18+0.09 0.59+0.04 (52.2± 3.2)
ML-1 1.19+0.08 0.80+0.04 (65.5±4.5)
Lymphocytes, PHA (-) 0.26+0.02 0.07+0.01 (33.6±3.1)
Lymphocytes, PHA (+) 0.66+0.07 0.08+0.01 (15.8± 1.6)
Treatment (A); 12h incubation in medium with 0.05,uCi 3H-VCR
and 10 iM dipyridamole.
Treatment (B); After treatment (A) 12h incubation in medium
without 3H-VCR or dipyridamole.
Values are means+s.d. for triplicate determinations on MOLT-3,
BL-TH and ML-1 cells, and 4 determinations on lymphocytes.
Retention of 3H-VCR by malignant cell lines was significantly
higher than that by lymphocytes (P<0.01).
15.8+1.6% and 33.6+3.1%, respectively, of those initially
(Table III). Thus, the efflux of VCR from normal lympho-
cytes was more rapid than that from malignant cell lines
(P<O.O1).
Discussion
The salvage pathway is important for supply of nucleosides
for DNA biosynthesis in some malignant cells, because
nucleosides reverse the cytotoxic effects of MTX and acivicin
on the in vitro growth of these cells (Pinedo et al., 1976;
Howell et al., 1981). Moreover dipyridamole has been shown
to inhibit transport of purine and pyrimidine nucleosides
through the cell membrane (Scholtissek, 1968; Berlin &
Oliver, 1975), and to inhibit growth of tumour cells by
blocking nucleoside transport through the salvage pathway
(Zhen et al., 1983). Previously, we found that the ratio of
thymidine kinase to cytidine 5'-diphosphate reductase
activity was high in cultured myelo-monocytoid cell lines.
This finding also suggests the importance of the salvage
pathway in DNA synthesis of myelo-monocytoid type
haematologic malignancies (Takeda et al., 1984). We also
demonstrated that dipyridamole caused dose- and time-
dependent inhibition of 14C-TdR incorporation into cultured
human haemopoietic cell lines, and that dipyridamole
markedly inhibited the growth of peroxidase-positive myelo-
monocytoid cell lines (Hirose et al., 1986). These findings
suggested that dipyridamole might be useful as a new anti-
cancer agent with a different mechanism of action from
those of many other anti-cancer drugs.
On the basis of this hypothesis, the effects of dipyridamole
plus PALA, dipyridamole plus acivicin and dipyridamole
plus MTX have been tested and shown to be more effective
than either of the respective drugs alone: King & Howell
(1982) tested the effect of dipyridamole plus PALA (N-
phosphonacetyl-L-aspartate), an inhibitor of de novo
pyrimidine synthesis, and showed that dipyridamole substan-
tially inhibited uridine uptake by neoplastic human cells, and
caused about a 4-fold increase in the cytotoxicity of PALA.
Zhen et al. (1983) and Fischer et al. (1984) tested the effect
of dipyridamole plus acivicin on the growth of hepatoma
3924A and VACO5 cells, respectively, and showed that the
protections provided by the nucleosides were blocked by
dipyridamole. Moreover, Cabral et al. (1984) showed that
dipyridamole enhanced MTX accumulation by sarcoma 180
cells and diminished the efflux of the drug. Nelson & Drake
(1984) also tested the effect of this combination and showed
that dipyridamole enhanced the toxicity of MTX on cells in
culture and in mice.
On the contrary, dipyridamole reduced cytarabine uptake
by normal mouse cells, and by L1210 murine leukaemia and
HL-60 human leukaemia cells (King et al., 1984).GROWTH INHIBITION BY DIPYRIDAMOLE 417
We tested the effect of dipyridamole plus VCR for the
first time in the present study. We found that these com-
pounds had synergistic inhibitory effects on in vitro growth
of cultured cells and that dipyridamole enhanced VCR
accumulation in malignant haematologic cells. Dipyridamole
also enhanced VCR accumulation in normal lymphocytes,
but the efflux of VCR from normal lymphocytes was more
rapid than that from malignant cells. Cytochalasin B, which
enhances the accumulations of VCR and daunomycin in
tumour cells, inhibits actin polymerization and binds to the
cell membrane. Verapamil, a calcium channel blocker, also
strongly inhibits outward transport of VCR. The mechanism
of action of verapamil seems to be different from that of
cytochalasin (Tsuruo & lida, 1986). Dipyridamole seems to
block entry of nucleosides and nucleoside analogues by
binding tightly to the plasma membrane (Kessel & Dodd,
1972; Paterson et al., 1980), although its exact mechanism of
action is unknown. Further information on the mechanisms
of membrane transport of drugs should be helpful in
developing more effective methods of drug administration.
Dipyridamole is a vasodilator and antithrombotic agent,
which has been used in the treatment of angina pectoris,
while VCR is one of the most widely used anti-cancer drugs.
Our results suggest that VCR should be more effective in the
treatment of leukaemia and lymphoma when administered in
combination with dipyridamole.
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